📊 ISCO Key Takeaways
Is ISCO a Good Investment? Thesis Analysis
International Stem Cell Corporation exhibits severe financial distress with negative stockholders' equity of -$3.8M, indicating the company is technically insolvent. Despite modest revenue growth of 16.6% YoY to $6.9M, the company burns cash operationally (-$24K OCF) and has negative free cash flow of -$64K, with dangerously low liquidity ratios that threaten near-term viability.
Why Buy ISCO? Key Strengths
- Revenue growth of 16.6% YoY demonstrates demand for core products/services
- Positive operating income of $46K shows some operational profitability before capital structure effects
- Cash position of $966K provides minimal runway for operations
ISCO Investment Risks to Consider
- Negative stockholders' equity of -$3.8M indicates technical insolvency and existential solvency risk
- Current ratio of 0.80x and quick ratio of 0.46x show severe liquidity crisis with current liabilities exceeding current assets
- Negative free cash flow of -$64K combined with operating cash burn suggests inability to fund operations or growth without capital injection
- Interest coverage ratio of 0.4x indicates inability to service debt obligations from operating earnings
- No insider buying activity in last 90 days suggests lack of confidence from management
Key Metrics to Watch
- Operating cash flow trend and path to cash flow positivity
- Stockholders' equity recovery and balance sheet restructuring
- Revenue sustainability and gross margin realization if disclosed
- Cash runway duration given current burn rate
- Debt restructuring or equity infusion announcements
ISCO Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ISCO Profitability Ratios
ISCO vs Healthcare Sector
How International Stem Cell CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ISCO Overvalued or Undervalued?
Based on fundamental analysis, International Stem Cell CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ISCO Balance Sheet & Liquidity
ISCO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: International Stem Cell CORP's revenue has remained relatively flat over the 5-year period, with a 4% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
ISCO Growth Metrics (YoY)
ISCO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.2M | $57.0K | $0.00 |
| Q2 2025 | $2.3M | -$95.0K | $-0.01 |
| Q1 2025 | $2.1M | -$214.0K | $-0.03 |
| Q3 2024 | $2.0M | -$34.0K | $0.02 |
| Q2 2024 | $1.8M | -$34.0K | $-0.01 |
| Q1 2024 | $2.1M | -$34.0K | $-0.03 |
| Q3 2023 | $1.7M | -$2.0K | $0.02 |
| Q2 2023 | $1.8M | -$2.0K | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ISCO Capital Allocation
ISCO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for International Stem Cell CORP (CIK: 0001355790)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ISCO
What is the AI rating for ISCO?
International Stem Cell CORP (ISCO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ISCO's key strengths?
Claude: Revenue growth of 16.6% YoY demonstrates demand for core products/services. Positive operating income of $46K shows some operational profitability before capital structure effects.
What are the risks of investing in ISCO?
Claude: Negative stockholders' equity of -$3.8M indicates technical insolvency and existential solvency risk. Current ratio of 0.80x and quick ratio of 0.46x show severe liquidity crisis with current liabilities exceeding current assets.
What is ISCO's revenue and growth?
International Stem Cell CORP reported revenue of $6.9M.
Does ISCO pay dividends?
International Stem Cell CORP does not currently pay dividends.
Where can I find ISCO SEC filings?
Official SEC filings for International Stem Cell CORP (CIK: 0001355790) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ISCO's EPS?
International Stem Cell CORP has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ISCO a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, International Stem Cell CORP has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ISCO stock overvalued or undervalued?
Valuation metrics for ISCO: ROE of N/A (sector avg: 15%), net margin of -1.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ISCO stock in 2026?
Our dual AI analysis gives International Stem Cell CORP a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ISCO's free cash flow?
International Stem Cell CORP's operating cash flow is $-24.0K, with capital expenditures of $40.0K. FCF margin is -0.9%.
How does ISCO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.80 (avg: 2).